Here, the authors show that MICU1 is upregulated in ovarian cancer and confers resistance to cisplatin-induced apoptosis through a Ca2+-mediated regulation of pyruvate dehydrogenase activity that results in increased glycolysis. Here, MICU1 is linked to ovarian cancer.